National Aeronautics and Space Administration



Exploration Medical Capability (ExMC) Science and Research: Overview and Update

Benjamin Easter, MD, MBA, FACEP, AFaSMA Acting Element Scientist

Jay Lemery, MD, FACEP
Associate Element Scientist

Kris Lehnhardt, MD, FACEP, FASMA Element Scientist



NASA Human Research Program Investigators' Workshop 7 February 2023







Our Mission





Advance medical system design and risk-informed decision-making for exploration beyond low Earth orbit to promote human health and performance in space



ExMC Risks



Risk of Adverse Health Outcomes & Decrements in Performance due to Medical Conditions that occur In Mission

Ineffective/ Toxic Medications During Long-Duration Exploration Spaceflight

DRM	Mission Type	Operations		Long-Term Health		DBM Categories	Mission Type	Operations		Long-Term Health	
Categories	and Duration	LxC	Risk Disposition *	LxC	Risk Disposition *	DRM Categories	and Duration	LxC	Risk Disposition *	LxC	Risk Disposition *
Low Earth	Short (<30 days)	3x2	Accepted	3x2	Accepted	Low Earth	Short (<30 days)	1x1	Accepted	1x1	Accepted
Orbit	Long (30 days-1 year)	4x2	Accepted	4x2	Accepted	Orbit	Long (30 days-1 year)	1x1	Accepted	1x1	Accepted
Lunar Orbital	Short (<30 days)	4x2	Accepted	3x2	Accepted	Lunar Orbital	Short (<30 days)	2x1	Accepted	1x1	Accepted
Luliai Olbitai	Long (30 days-1 year)	5x3	Requires Mitigation	4x2	Requires Characterization	Lunai Orbitat	Long (30 days-1 year)	3x2	Accepted with Optimization	2x2	Accepted with Monitoring
Lunar Orbital	Short (<30 days)	4x3	Requires Characterization	4x2	Requires Characterization	Lunar Orbital	Short (<30 days)	3x1	Accepted with Optimization	2x1	Accepted with Monitoring
+ Surface	Long (30 days-1 year)	5x4	Requires Mitigation	4x4	Requires Characterization	+ Surface	Long (30 days-1 year)	4x2	Accepted with Optimization	2x2	Accepted with Monitoring
Mars	Preparatory (<1 year)	5x4	Requires Mitigation	4x4	Requires Characterization	Mars	Preparatory (<1 year)	4x3	Requires Characterization	3x2	Accepted with Monitoring
	Mars Planetary (730-1224 days)	5x5	Requires Mitigation	5x4	Requires Characterization	mais	Mars Planetary (730-1224 days)	5x3	Requires Mitigation	5x3	Requires Mitigation

Human Research Roadmap





ExMC Risks



Risk of Adverse Health and Performance Effects of Celestial Dust Exposure

DRM	Mission Type and	O	perations	Long-Term Health		
Categori	Duration	LxC	Risk Disposition *	LxC	Risk Disposition *	
Low Fart	Short (<30 days)	Not Applicable	Not Applicable	Not Applicable	Not Applicable	
Orbit	Long (30 days-1 year)	Not Applicable	Not Applicable	Not Applicable	Not Applicable	
Lunar	Short (<30 days)	1x2	Accepted	1x2	Accepted	
Lunar Orbital	Long (30 days-1 year)	1x2	Accepted	1x2	Accepted	
Lunar	Short (<30 days)	2x2	Accepted	2x3	Requires Mitigation	
Orbital + Surfac	LONS	3x3	Requires Mitigation	3x4	Requires Mitigation	
	Preparatory (<1 year)	Not Applicable	Not Applicable	Not Applicable	Not Applicable	
Mars	Mars Planetary (730-1224 days)	4x4	Requires Characterization	4x4	Requires Characterization	

Risk of Renal Stone Formation

DRM Categories	Mission Type and		Operations	Long-Term Health		
DRM Categories	Duration	LxC	Risk Disposition *	LxC	Risk Disposition *	
Low Earth Orbit	Short (<30 days)	1x4	Accepted with Monitoring	1x3	Accepted with Monitoring	
LOW Earth Orbit	Long (30 days-1 year)	3x4	Accepted with Monitoring	2x3	Accepted with Monitoring	
Lunar Orbital	Short (<30 days)	1x4	Accepted with Monitoring	1x3	Accepted with Monitoring	
Luliai Olbitai	Long (30 days-1 year)	3x4	Accepted with Monitoring	2x3	Accepted with Monitoring	
Lunar Orbital	Short (<30 days)	1x4	Accepted with Monitoring	1x3	Accepted with Monitoring	
+ Surface	Long (30 days-1 year)	3x4	Accepted with Monitoring	2x3	Accepted with Monitoring	
Mars	Preparatory (<1 year)	3x4	Requires Mitigation	3x4	Requires Mitigation	
mais	Mars Planetary (730-1224 days)	4x4	Requires Mitigation	4x4	Requires Mitigation	

Human Research Roadmap





Focus Areas





- Scientific publications
- Clinical evidence for trade space tools

Scientific & Clinical Research

Technology Demonstrations

Systems Engineering

- Concepts of Operations
- Requirements development
- Model-based Systems Engineering
- Trade space analysis

- Diagnostic and treatment technologies for exploration missions
- Medical Autonomy





ACCOMPLISHMENTS – 2022

CURRENT AND FUTURE EFFORTS – 2023 AND BEYOND



Accomplishments – Long Duration Lunar Orbital and Lunar Surface (LDLOLS) Medical System Foundation



Medical System Foundation for Level of Care IV: Long **Duration Lunar Orbit and Lunar Surface**

Medical System Content

A Medical System Foundation is a system model that contains both Systems Engineering products and Clinical Data. It is meant to serve as a starting point for NASA programs that are developing mission- and vehicle- specific medical systems. New users of this web report are recommended to reference the accompanying context, process and history document while viewing the report: Medical System Foundation for LoC IV LDLOLS Context Process and Project

The Medical System is a subsystem of the Crew Health and Performance (CHP) system; it interfaces with the other CHP subsystems and vehicle systems external to the CHP system. The Medical System Foundation model captures systems engineering and clinical content and the relationships that exist between and among them. The model includes a Concept of Operations (ConOps), a list of functions traceable to the ConOps content, requirements derived from the functions, a set of medical conditions that could occur in-flight, medical capabilities, and example resources that could be used to diagnose or treat these conditions

Information about the Medical System Foundation





Contact Information




Glossary and





Developed a Medical System Foundation for Extended/Sustaining Artemis missions and Mars Transit Hab

- Concept of Operations
- Medical condition, clinical capability, and resource sets
- System Model with Requirements and traces
- Intended to be a starting point (a "Foundation") for early medical system design to build from and that can be tailored for specific missions
- Coming soon to ExMC public website with:
 - Short training videos
 - Readable in standard web browser







Future – Earth Independent Medical Operations (EIMO)






- Aspirational title
- Progressive transfer of autonomy and decision-making for exploration missions
- FY23- Define Vision and Concept of Operations
- FY24+
 - –Medical Training
 - Decision Support
 - Medical Ops with comm latency
 - -Requirements



Accomplishments – IMPACT v1.0



IMPACT = Informing Mission Planning via Analysis of Complex Tradespaces




- Probabilistic Risk Assessment (PRA) model and Tradespace analysis tool suite
- Expanded to 120 medical conditions, ~700 clinical resources
- Baselined to lunar missions
- Successor to IMM
- Now "pencils down" and completing verification, validation, and credibility (VV+C)



Future – IMPACT



IMPACT = Informing Mission Planning via Analysis of Complex Tradespaces



v1.0


- Delivery Mar 2023
- Transition to Operations 2023
- Operational FY24
- v1.x
 - FY24 and following
 - New capabilities and conditions
- v2.0
 - Expand from medical to Crew
 Health and Performance
- Considering options to make IMPACT (results) available external to NASA




Accomplishments – Pharm Risk



Analysis of the Effect of Spaceflight on Drug Potency to Quantify the Risk of Medication Failure for Exploration Space Missions



- Pre-print of quantitative assessment of medication stability
- New Pharmacokinetics Strategy
- MOU with USAF to analyze additional spaceflight flown pharmaceuticals





Future – Pharm Risk





- New Pharm Stability Evidence Report
 - Will be publicly available

- MOU with USAF to analyze additional spaceflight flown pharmaceuticals
- VacuuMed study on Polaris
 Dawn
 - Stability of meds on exposure to vacuum



Accomplishments - rHEALTH ONE® Tech Demo







Trade names and trademarks are used in this report for identification only. Their usage does not constitute an official endorsement, either expressed or implied, by the National Aeronautics and Space Administration.





Read 28 replies

 Point-of-care lab analysis device to monitor clinical and research biomarkers


- Developed with SBIR funds, now COTS technology
- Successful in-flight performance



Future – Tech Demos Tempus ALS®







- Multifunctional medical device
- Collaboration with ESA and XMIPT
- Phase 1
 - Periodic Health Status (PHS)Exam
 - On-orbit contingency drill
- Phase 2
 - Medical contingency simulation
 - Comms: real-time, seconds, minutes
 - Procedural guidance

Trade names and trademarks are used in this report for identification only. Their usage does not constitute an official endorsement, either expressed or implied, by the National Aeronautics and Space Administration.

National Aeronautics and Space Administration



Questions?

benjamin.easter@nasa.gov